185 related articles for article (PubMed ID: 30425091)
1. Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.
Rachner TD; Kasimir-Bauer S; Göbel A; Erdmann K; Hoffmann O; Browne A; Wimberger P; Rauner M; Hofbauer LC; Kimmig R; Bittner AK
Clin Cancer Res; 2019 Feb; 25(4):1369-1378. PubMed ID: 30425091
[TBL] [Abstract][Full Text] [Related]
2. Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer.
Elfar GA; Ebrahim MA; Elsherbiny NM; Eissa LA
Oncol Res; 2017 Apr; 25(4):641-650. PubMed ID: 27983911
[TBL] [Abstract][Full Text] [Related]
3. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
4. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
[TBL] [Abstract][Full Text] [Related]
5. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
6. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
7. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
[TBL] [Abstract][Full Text] [Related]
8. Possible Prognostic Potential of RANKL and OPG in Metastatic Breast Cancer Egyptian Females.
Shaker OG; Elbaz EM
Asian Pac J Cancer Prev; 2020 Feb; 21(2):355-361. PubMed ID: 32102511
[TBL] [Abstract][Full Text] [Related]
9. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
[TBL] [Abstract][Full Text] [Related]
11. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Kawamura K; Imamoto T; Takanami M; Ichikawa T
Int J Clin Oncol; 2011 Aug; 16(4):366-72. PubMed ID: 21327451
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
[TBL] [Abstract][Full Text] [Related]
13. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
14. Bone metastases detection by circulating biomarkers: OPG and RANK-L.
Mercatali L; Ibrahim T; Sacanna E; Flamini E; Scarpi E; Calistri D; Ricci M; Serra P; Ricci R; Zoli W; Kang Y; Amadori D
Int J Oncol; 2011 Jul; 39(1):255-61. PubMed ID: 21491082
[TBL] [Abstract][Full Text] [Related]
15. Circulating Bone-related Markers and YKL-40 Versus HER2 and TOPO2a in Bone Metastatic and Nonmetastatic Breast Cancer: Diagnostic Implications.
Shaker OG; Helmy HS
Clin Breast Cancer; 2018 Jun; 18(3):e321-e328. PubMed ID: 28645722
[TBL] [Abstract][Full Text] [Related]
16. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
17. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.
Sänger N; Ruckhäberle E; Bianchini G; Heinrich T; Milde-Langosch K; Müller V; Rody A; Solomayer EF; Fehm T; Holtrich U; Becker S; Karn T
Mol Oncol; 2014 Oct; 8(7):1196-207. PubMed ID: 24785095
[TBL] [Abstract][Full Text] [Related]
18. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
19. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin levels and mammographic density among high-risk women.
Moran O; Zaman T; Eisen A; Demsky R; Blackmore K; Knight JA; Elser C; Ginsburg O; Zbuk K; Yaffe M; Narod SA; Salmena L; Kotsopoulos J
Cancer Causes Control; 2018 Jun; 29(6):507-517. PubMed ID: 29679262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]